We have located links that may give you full text access.
Journal Article
Review
Oral Xa inhibitors.
Hematology/oncology Clinics of North America 2010 August
Several new oral drugs that selectively and directly inhibit factor Xa seem promising alternatives to existing antithrombotic drugs. These drugs have a convenient route of administration, can be given in fixed doses, and do not require coagulation monitoring. Favorable results of clinical trials support their potential to change current practice. Translation into daily clinical practice may take some time; clinical studies over the next months and years will reveal the impact of rivaroxaban and other compounds in development. The aim of this review is to provide an overview of the more advanced oral, direct factor Xa inhibitors and to briefly describe the results of the completed studies.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app